Johnson & Johnson Stock Price, News & Analysis

Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.06 per share for the first quarter of 2022. This dividend payment is scheduled for March 8, 2022, to shareholders on record as of February 22, 2022, with an ex-dividend date of February 18, 2022. The announcement underscores the company's commitment to returning value to its shareholders while continuing its mission to improve health outcomes globally.

Johnson & Johnson (NYSE: JNJ) reported positive preliminary results from the South African Phase 3b Sisonke study, indicating an 85% effectiveness of its COVID-19 vaccine booster against hospitalization during the Omicron variant surge. The study involved healthcare workers and revealed that vaccine effectiveness increased over time post-boost. Additionally, a separate analysis showed that a heterologous booster regimen significantly enhanced immune responses compared to a homologous booster. These findings underscore the robustness of the Johnson & Johnson vaccine amidst evolving COVID-19 variants.

The CHMP of the EMA issued a Positive Opinion for Johnson & Johnson's COVID-19 vaccine booster, recommending it for adults 18+ at least two months post-initial vaccination. The booster increased protection to 75% against symptomatic COVID-19 and demonstrated 100% protection against severe cases, with data from the Phase 3 ENSEMBLE 2 study. The vaccine was generally well-tolerated, showing no new safety concerns. The recommendation supports its use as a 'mix and match' booster.

Johnson & Johnson (NYSE: JNJ) will hold a conference call on January 25, 2022, at 8:30 a.m. Eastern Time to discuss its fourth-quarter results. The call will feature key executives, including Joaquin Duato, the incoming CEO. Investors can access the call via the company's website and by phone. A replay will be available until February 8, 2022. The earnings report will be released at approximately 6:45 a.m. Eastern Time on the same day. For future events, please visit Johnson & Johnson's investor relations page.

Johnson & Johnson (NYSE: JNJ) received interim recommendations from the WHO's Strategic Advisory Group of Experts (SAGE) supporting its COVID-19 vaccine as a booster shot for individuals 18 and older, to be given 2 to 6 months post the primary vaccination. The booster enhances protection against symptomatic infections and severe disease. The recommendations are based on data from clinical trials and Phase 3 studies. The company is committed to delivering up to 900 million doses to the African Union and COVAX by 2022, ensuring accessibility amid the pandemic.

Johnson & Johnson (NYSE: JNJ) announced key appointments to its Executive Committee, following the retirement of Michael Sneed, effective April 1, 2022. Joaquin Duato will succeed Alex Gorsky as CEO on January 3, 2022. New executive roles include Vanessa Broadhurst as Executive VP of Global Corporate Affairs and Mathai Mammen as Executive VP of Pharmaceuticals, R&D. The leadership changes aim to strengthen company strategy and execution, as highlighted by Duato, who emphasized the team's dedication to the company's mission.

On December 5, 2021, Johnson & Johnson (NYSE: JNJ) announced preliminary findings from a study indicating that a booster shot of its COVID-19 vaccine, Ad26.COV2.S, significantly enhances antibody and T-cell responses when administered six months post a two-dose regimen of BNT162b2. Conducted by Dan Barouch, M.D., Ph.D., the study suggests a mix-and-match approach could yield superior immune responses. Results also align with previous UK studies showcasing increased immunogenicity with Johnson & Johnson's vaccine. The CDC recommends this booster for all eligible individuals.

Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) will present data from six studies on its respiratory syncytial virus (RSV) vaccine candidate at the Eighth European Scientific Working Group on Influenza meeting. Highlights include findings from the Phase 2b CYPRESS trial, showing 80% effectiveness against lower respiratory infections. The vaccine candidate has received Breakthrough Therapy Designation from the FDA and is currently in Phase 3 trials. The urgent need for an RSV vaccine remains, as no effective treatments exist for older adults at high risk.

Johnson & Johnson (NYSE: JNJ) announced plans to spin off its Consumer Health business, creating two independent companies. The split aims to enhance focus, agility, and innovation in healthcare, positioning the new Johnson & Johnson as a leader in pharmaceuticals and medical devices, projected to generate $77 billion in revenue for FY 2021. The New Consumer Health Company will be a global leader in health products with $15 billion projected revenue. The separation is expected to be tax-free for U.S. federal purposes and is targeted for completion within 18-24 months, pending regulatory approvals.